Core Viewpoint - The stock of Baixinan-B (02185) surged nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, marking a significant milestone for the company in the renal denervation market [1] Group 1: Company Developments - Baixinan-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - The TRA method enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] Group 2: Market Position and Goals - The company's ultimate goal is to provide outpatient renal denervation surgeries to patients worldwide [1] - The Iberis RDN system received CE marking in Europe in 2016, indicating its established presence in the international market [1]
百心安-B午后涨近12% IBERIS RDN系统在新西兰注册